Kanishk Kumar: Thalassemia Pipeline 2025 Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared a post on LinkedIn:
”Thalassemia Pipeline 2025: Addressing Hemoglobin Deficiencies in Inherited Blood Disorders
Thalassemia, a group of inherited blood disorders causing reduced hemoglobin synthesis and chronic anemia, is advancing with innovative therapies in 2025. The Thalassemia Pipeline features 25+ pharmaceutical firms developing 28+ investigational medications, from gene editing to small molecules, aimed at increasing hemoglobin levels, reducing transfusion dependency, and improving quality of life for patients with varying severity.
Key Developments in Thalassemia Treatment:
Etavopivat by Novo Nordisk, a PKR activator in Phase III, aims to improve red blood cell health and reduce anemia in thalassemia by enhancing oxygen affinity and decreasing hemolysis.
CS-101 by Correct Sequence Therapeutics, a gene editing therapy in Phase I, reactivates fetal hemoglobin production for a potential lifetime cure using the patient’s own stem cells.
Leading Thalassemia Companies include Novo Nordisk , Kind Pharmaceuticals LLC, Correct Sequence Therapeutics , Editas Medicine, San Rocco Therapeutics, Lantu Biopharma, Regeneron , Kanglin Biotec, Shanghai BDgene Co., Ltd., BioRay Pharmaceutical , Celgene, Mabwell , among others.
Promising therapies include Etavopivat, AND017, CS101, among others.
DelveInsight’s comprehensive report on the Thalassemia Pipeline Analysis 2025․՛՛
Stay updated with Hemostasis Today.
-
Oct 3, 2026, 06:11Ana Cespedes: Maternal Anemia in Pregnancy Linked to Differences in Infant Brain Structure
-
Oct 3, 2026, 05:52Kemal Karaagac: When Vitamin K Antagonists Remain Essential in Cardiac Care
-
Oct 3, 2026, 05:32Shiavax J. Rao: PERT 2026 Session Explores Long-Term Anticoagulation and DOAC Management
-
Oct 3, 2026, 05:13Parveen Yograj: Iron Deficiency and Anaemia – Diagnosis, Causes, and Treatment Guidelines
-
Oct 3, 2026, 00:25Antiplatelets May Be a Strong Option After Ischemic Stroke in Active Cancer – International Journal of Stroke
-
Oct 3, 2026, 00:24Mavis Agnes Kisakye: Honored to Join UNHLS Leadership in Advancing HIV Diagnostics in Uganda
-
Oct 3, 2026, 00:23Phil Spinella: Blood is for Bleeding, Salt Water is for Cooking pasta, Keeping it simple
-
Oct 3, 2026, 00:21Pablo Corral: The ANGPTL Axis in Dyslipidemia and Cardiovascular Risk
-
Oct 3, 2026, 00:20Raghavendra Rao: The Link Between Chronic Venous Disease and VTE May Be Less Robust Than Previously Thought